A notable advancement in diabetes management is emerging with the approval of tirzepatide in a 45mg form. This innovative version builds upon the existing success of tirzepatide, a dual GIP and GLP-1 agonist, and https://jimncxy699243.collectblogs.com/85508550/groundbreaking-development-tirzepatide-dose-for-diabetes-management